2022 Performance Summary Infographic - Bristol-Myers Squibb




Consistent with prior year or, an increase of 3% when excluding foreign exchange



In-Line Brand
YoY% growth



New Product Portfolio*
YoY% growth

Potential for risk-adjusted sales of $10-$13B revenues in 2025

Potential for $25B+ of non-risk adjusted revenues in 2030





Significant Pipeline Advancement in 2022

approvals in the US, EU and Japan

9 doc icon

approvals for Opdivo; Opdivo plusYervoy


positive registrational
topline readouts


invested in research
and development

Launched 3 First-In-Class Medicines
opdualag logo

For metastatic melanoma

Camzyos logo

For obstructive hypertrophic cardiomyopathy

sotyktu logo

For moderate to severe plaque psoriasis

Strategically Positioned for Multiple Waves of Innovation

new products launched over
~3 years3

15+ doc icon

additional indications over ~3 years3


high potential mid-late
stage registrational assets
across therapeutic areas

50+ doc icon

early-stage assets
in development

Balanced Approach to Capital Allocation

in cash flow from operating activities


Reduced debt by


Returned cash to shareholders


* New Product Portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets), Zeposia® (ozanimod), Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag® (relatlimab plus nivolumab), Camzyos® (mavacamten) and SotyktyuTM (deucravacitinib).

1 GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.

2 This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.

3 Portfolio achievements from 2H 2019-2022.

Includes $4.6 billion for dividends paid and $8.0 billion for common stock repurchases.





Annual Report 2022


There is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.